Medically unfit women with early-stage endometrial cancer treated with the levonorgestrel intrauterine system
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
ObjectiveTo assess the clinical efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the treatment of early-stageendometrial cancer in elderly morbidly obese women, whose multiple co-morbidities made the standard surgicaltreatment too risky to undertake. MethodsA retrospective review was conducted and case series reports were prepared of all women diagnosed withendometrial cancer, from April 2011 to December 2016 at the Queen's Hospital, London, to identify women unfit forsurgery and treated with the LNG-IUS. ResultsOut of 438 women with endometrial cancer, Eight women with early-stage endometrial cancer were deemed unfitfor surgery and underwent treatment with the LNG-IUS. All had grade 1 endometrioid endometrial adenocarcinoma,radiologically staged as 1a. Four women died of their co-morbidities, not related to endometrial cancer. One of themhad 68 months of progression-free survival before death due to co-morbidities. One patient required a hysterectomyafter 32 months of treatment with LNG-IUS and oral progestogens due to heavy vaginal bleeding. Three women havecontinued the LNG-IUS treatment with no evidence of progressive disease symptoms till date at a mean follow-up of35.7 months. ConclusionFor women with multiple co-morbidities, the LNG-IUS offers an effective and safe treatment for early-stage, lowgradeendometrial cancer, with no cases of symptomatic progression reported in our case series. In the frail andelderly, where the quality of life is of paramount importance, surgical treatment may not offer additional long-termsurvival benefits.
Abstract
ObjectiveTo assess the clinical efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the treatment of early-stageendometrial cancer in elderly morbidly obese women, whose multiple co-morbidities made the standard surgicaltreatment too risky to undertake. MethodsA retrospective review was conducted and case series reports were prepared of all women diagnosed withendometrial cancer, from April 2011 to December 2016 at the Queen's Hospital, London, to identify women unfit forsurgery and treated with the LNG-IUS. ResultsOut of 438 women with endometrial cancer, Eight women with early-stage endometrial cancer were deemed unfitfor surgery and underwent treatment with the LNG-IUS. All had grade 1 endometrioid endometrial adenocarcinoma,radiologically staged as 1a. Four women died of their co-morbidities, not related to endometrial cancer. One of themhad 68 months of progression-free survival before death due to co-morbidities. One patient required a hysterectomyafter 32 months of treatment with LNG-IUS and oral progestogens due to heavy vaginal bleeding. Three women havecontinued the LNG-IUS treatment with no evidence of progressive disease symptoms till date at a mean follow-up of35.7 months. ConclusionFor women with multiple co-morbidities, the LNG-IUS offers an effective and safe treatment for early-stage, lowgradeendometrial cancer, with no cases of symptomatic progression reported in our case series. In the frail andelderly, where the quality of life is of paramount importance, surgical treatment may not offer additional long-termsurvival benefits.
참고문헌 (33)
- Sletten ET, "Low-dose LNGIUS as therapy for endometrial hyperplasia. A prospective cohort pilot study", Anticancer Res, 38, pp.2883~2889 (2018)
- "Uterine cancer incidence statistics, risk, survival and mortality rates 2018" (2018)[URL]
- Schmandt RE, "Understanding obesity and endometrial cancer risk : opportunities for prevention", Am J Obstet Gynecol, 205, pp.518~525 (2011)
- Baker WD, "Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill postmenopausal women", Gynecol Oncol, 146, pp.34~38 (2017)
- Passarello K, "Endometrial cancer : an overview of pathophysiology, management, and care", Semin Oncol Nurs, 35, pp.157~165 (2019)
- Corzo C, "Updates on conservative management of endometrial cancer", J Minim Invasive Gynecol, 25, pp.308~313 (2018)
- Gunderson CC, "Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma : a systematic review", Gynecol Oncol, 125, pp.477~482 (2012)
- Chiva L, "Sparing fertility in young patients with endometrial cancer", Gynecol Oncol, 111(Supp), pp.S101~104 (2008)
- Gallos ID, "Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia : a systematic review and metaanalysis", Am J Obstet Gynecol, 207, pp.266.e1~266.e12 (2012)
- Rodolakis A, "European Society of Gynecological Oncology task force for fertility preservation : clinical recommendations for fertility-sparing management in young endometrial cancer patients", Int J Gynecol Cancer, 25, pp.1258~1265 (2015)
- Dhar KK, "Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature", Gynecol Oncol, 97, pp.924~927 (2005)
- Giannopoulos T, "Levonorgestrel-releasing intrauterine system(LNG-IUS)as a therapy for endometrial carcinoma", Gynecol Oncol, 95, pp.762~764 (2004)
- Bouwman F, "The impact of BMI on surgical complications and outcomes in endometrial cancer surgery--an institutional study and systematic review of the literature", Gynecol Oncol, 139, pp.369~376 (2015)
- Rolston A, "Factors associated with outcomes and inpatient 90-day cost of care in endometrial cancer patients undergoing hysterectomy-implications for bundled care payments", Gynecol Oncol, 150, pp.106~111 (2018)
- Caldwell G, "Mirenas against malignancy : an alternative to operative management", J Obstet Gynaecol, 38, pp.731~ (2018)
- Yuk JS, "Levonorgestrel-releasing intrauterine systems versus oral cyclic medroxyprogesterone acetate in endometrial hyperplasia therapy : a meta-analysis", Ann Surg Oncol, 24, pp.1322~1329 (2017)
- Macchia G, "Progestin-releasing intrauterine device insertion plus palliative radiotherapy in frail, elderly uterine cancer patients unfit for radical treatment", Oncol Lett, 11, pp.3446~3450 (2016)
- Montz FJ, "Intrauterine progesterone treatment of early endometrial cancer", Am J Obstet Gynecol, 186, pp.651~657 (2002)
- Morelli M, "Efficacy of the levonorgestrel intrauterine system(LNG-IUS)in the prevention of the atypical endometrial hyperplasia and endometrial cancer : retrospective data from selected obese menopausal symptomatic women", Gynecol Endocrinol, 29, pp.156~159 (2013)
- Wildemeersch D, "Safety and comfort of long-term continuous combined transdermal estrogen and intrauterine levonorgestrel administration for postmenopausal hormone substitution-a review", Gynecol Endocrinol, 32, pp.598~601 (2016)
- Orbo A, "Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia : a national multicentre randomised trial", BJOG, 121, pp.477~486 (2014)
- Soini T, "Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube", Acta Oncol, 55, pp.1281~1284 (2016)
- Soini T, "Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland", Obstet Gynecol, 124, pp.292~299 (2014)
- Jareid M, "Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study", Gynecol Oncol, 149, pp.127~132 (2018)
- Mørch LS, "Contemporary hormonal contraception and the risk of breast cancer", N Engl J Med, 377, pp.2228~2239 (2017)
- Francesca Falcone, "Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer", Journal of Gynecologic Oncology, 28(1), pp.1~12 (2017), 대한부인종양학회[DOI]
- Heyman J, "The radiotherapeutic treatment of cancer corporis uteri", Br J Radiol, 20, pp.85~91 (1947)
- van der Steen-Banasik E, "Primary brachytherapy as a radical treatment for endometrial carcinoma", J Contemp Brachytherapy, 6, pp.106~112 (2014)
- Dankulchai P, "Imageguided high-dose-rate brachytherapy in inoperable endometrial cancer", Br J Radiol, 87, pp.20140018~ (2014)
- Kucera H, "Treatment of endometrial carcinoma with high-dose-rate brachytherapy alone in medically inoperable stage I patients", Acta Obstet Gynecol Scand, 77, pp.1008~1012 (1998)
- Nguyen TV, "High-dose-rate brachytherapy for medically inoperable stage I endometrial cancer", Gynecol Oncol, 71, pp.196~203 (1998)
- Jordan SE, "Image-guided high-dose-rate intracavitary brachytherapy in the treatment of medically inoperable early-stage endometrioid type endometrial adenocarcinoma", Brachytherapy, 16, pp.1144~1151 (2017)
- Petereit DG, "Perioperative morbidity and mortality of high-dose-rate gynecologic brachytherapy", Int J Radiat Oncol Biol Phys, 42, pp.1025~1031 (1998)